Lingling Fu
Lingling Fu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Runhui Wu
Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
5 shared publications Jie Ma
Beijing Children's Hospital Capital Medical University
3 shared publicationsJingyao Ma
3 shared publicationsYunyun Wei
3 shared publicationsBixi Yang
Beijing Children's Hospital Capital Medical University
2 shared publicationsHao Gu
Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health Beijing Key Laboratory of Pediatric Hematology Oncology Beijing China
2 shared publications
Latest Publications
- Open Access
- 11 February 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (2)
Stepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent/chronic immune thrombocytopenia: a multicenter prospective study from China
- 11 February 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (2)
Open AccessStepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent/chronic immune thrombocytopenia: a multicenter prospective study from China
- Open Access
- 14 October 2022
- Published by Wiley
A single-center historical control study of eltrombopag combined with immunosuppressive therapy for severe aplastic anemia in children
Severe aplastic anemia (SAA) is caused by immune-mediated destruction. Standard immunosuppressive therapy (IST) is effective, but needs to be improved. A total of 115 patients (60 males; median age of 5.77 years and median follow-up time of 45 months) were enrolled in this historical control study. The complete response (CR) rates in the eltrombopag group were 30.3% at 3 months, 50.0% at 6 months, conpared to 8.2% at 3 months, 10.2% at 6 months in the control group. There were significant differences between the two groups at 3 months and 6 months after IST. The overall response rates in the two groups showed no significant differences during the study. There were significant differences in the times separated from granulocyte colony stimulating factor (G-CSF) G-CSF, red blood cell transfusion and Platelet transfusion between the two groups. Overall survival rates were 97.0% in the eltrombopag group and 96.0% in the control group (P=0.998). In the eltrombopag group 10.2% cases relapsed compared to 4.1% in the control group (P=0.703). No case progressed to myelodysplastic syndrome or myeloid leukemia in the eltrombopag group; one patient (2.0%) progressed to myelodysplastic syndrome in the control group. Totally 11 patients (16.7%) showed myeloid gene mutations in the eltrombopag group. Event-free survival (EFS) was 66.6% in the eltrombopag group and 57.1% in the control group. There were no significant differences in EFS between the two groups (P=0.967). In the eltrombopag group the common adverse reactions were transient and reversible hyperbilirubinemia, elevated liver enzymesand hyperuricemia.
- 14 October 2022
- Published by Wiley
Open AccessA single-center historical control study of eltrombopag combined with immunosuppressive therapy for severe aplastic anemia in children
Severe aplastic anemia (SAA) is caused by immune-mediated destruction. Standard immunosuppressive therapy (IST) is effective, but needs to be improved. A total of 115 patients (60 males; median age of 5.77 years and median follow-up time of 45 months) were enrolled in this historical control study. The complete response (CR) rates in the eltrombopag group were 30.3% at 3 months, 50.0% at 6 months, conpared to 8.2% at 3 months, 10.2% at 6 months in the control group. There were significant differences between the two groups at 3 months and 6 months after IST. The overall response rates in the two groups showed no significant differences during the study. There were significant differences in the times separated from granulocyte colony stimulating factor (G-CSF) G-CSF, red blood cell transfusion and Platelet transfusion between the two groups. Overall survival rates were 97.0% in the eltrombopag group and 96.0% in the control group (P=0.998). In the eltrombopag group 10.2% cases relapsed compared to 4.1% in the control group (P=0.703). No case progressed to myelodysplastic syndrome or myeloid leukemia in the eltrombopag group; one patient (2.0%) progressed to myelodysplastic syndrome in the control group. Totally 11 patients (16.7%) showed myeloid gene mutations in the eltrombopag group. Event-free survival (EFS) was 66.6% in the eltrombopag group and 57.1% in the control group. There were no significant differences in EFS between the two groups (P=0.967). In the eltrombopag group the common adverse reactions were transient and reversible hyperbilirubinemia, elevated liver enzymesand hyperuricemia.
- Open Access
- 8 March 2022
- Published by Springer Nature in Research Square
Summary and Analysis of 13 RAS-Associated Autoimmune Leukoproliferative Disease Clinical Features
Ras-associated autoimmune leukoproliferative disease (RALD) is a clinical syndrome, also known as autoimmune lymphoproliferative syndrome (ALPS) type IV, which is a primary immunodeficiency disease. However, there is still controversy about whether RALD is a chronic benign lymphoproliferative disease or a precancerous lesion. The clinical characteristics, laboratory examination results, treatment and prognosis of children with RALD treated in Beijing Children's Hospital were analyzed retrospectively. We reported 13 patients with RALD in our single center. The male-to-female ratio was 1.6:1, and the median age of onset was 6 months (range 2 months- 29 months). Eight patients (61.5%) had KRAS somatic mutations, and five patients (38.5%) had NRAS somatic mutations. The most common features were splenomegaly (12/13 cases), autoimmune cytopenia (9/13 cases), mononucleosis (10/13 cases), recurrent infection (7/13 cases), skin involvement (4/13 cases) and intestinal lesions (4/13 cases). Thirteen children were treated with immunotherapy, including glucocorticoids, intravenous immunoglobulin, cyclosporine, and sirolimus. The median follow-up time was 50 months (range 3 months-62 months). Four children died (2 cases of respiratory failure, 1 case of intestinal perforation and bleeding, and 1 case of sepsis with sudden respiratory and cardiac arrest). Nine children survived, seven children were treated with sirolimus, and no children developed malignant tumors of the hematopoietic system. In conclusion, RALD requires long-term follow-up to monitor malignant tumors, and sirolimus is effective for treatment.
- 8 March 2022
- Published by Springer Nature in Research Square
Open AccessSummary and Analysis of 13 RAS-Associated Autoimmune Leukoproliferative Disease Clinical Features
Ras-associated autoimmune leukoproliferative disease (RALD) is a clinical syndrome, also known as autoimmune lymphoproliferative syndrome (ALPS) type IV, which is a primary immunodeficiency disease. However, there is still controversy about whether RALD is a chronic benign lymphoproliferative disease or a precancerous lesion. The clinical characteristics, laboratory examination results, treatment and prognosis of children with RALD treated in Beijing Children's Hospital were analyzed retrospectively. We reported 13 patients with RALD in our single center. The male-to-female ratio was 1.6:1, and the median age of onset was 6 months (range 2 months- 29 months). Eight patients (61.5%) had KRAS somatic mutations, and five patients (38.5%) had NRAS somatic mutations. The most common features were splenomegaly (12/13 cases), autoimmune cytopenia (9/13 cases), mononucleosis (10/13 cases), recurrent infection (7/13 cases), skin involvement (4/13 cases) and intestinal lesions (4/13 cases). Thirteen children were treated with immunotherapy, including glucocorticoids, intravenous immunoglobulin, cyclosporine, and sirolimus. The median follow-up time was 50 months (range 3 months-62 months). Four children died (2 cases of respiratory failure, 1 case of intestinal perforation and bleeding, and 1 case of sepsis with sudden respiratory and cardiac arrest). Nine children survived, seven children were treated with sirolimus, and no children developed malignant tumors of the hematopoietic system. In conclusion, RALD requires long-term follow-up to monitor malignant tumors, and sirolimus is effective for treatment.
- Open Access
- 4 October 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (19) , 3799-3806
Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated thrombocytopenia and risk of hemorrhage. Treatment with eltrombopag increases and maintains hemostatic platelet counts; however, to date, long-term data are lacking on the outcome of children with ITP who are treated with eltrombopag. This prospective, observational, longitudinal cohort study evaluated the efficacy and safety of eltrombopag in pediatric patients with persistent or chronic ITP. For the 116 pediatric patients enrolled, duration of eltrombopag treatment was at least 3 months. Median effective dose was 25 mg/day, 50 mg/day, and 50 mg/day, respectively, for children age 5 years or younger, 6 to 11 years, or 12 years or older. In all, 89 patients (76.7%) achieved overall response, 53 (45.7%) achieved complete response, and 36 (31.0%) achieved response. Median platelet counts increased by week 1 and were sustained throughout the treatment period. During treatment with eltrombopag, the proportion of patients with grade 1 to 4 bleeding symptoms decreased from 83.61% at baseline to 9.88% at 6 months when only grade 1 was reported. Forty-three patients (37.1%) reported using concomitant medications at study entry, which was reduced to 1 patient (2.5%) who needed concomitant medications at 12 months. All adverse events were grade 1 or 2 according to Common Terminology Criteria for Adverse Events. No serious adverse events, cataracts, malignancies, or thromboses were reported during the study. Long-term treatment with eltrombopag was generally safe, well tolerated, and effective in maintaining platelet counts and reducing bleeding in most pediatric patients with persistent or chronic ITP. Combined with future studies, these findings will help establish how eltrombopag should best be used in the management of pediatric patients with East Asian ancestry.
- 4 October 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (19) , 3799-3806
Open AccessSpotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated thrombocytopenia and risk of hemorrhage. Treatment with eltrombopag increases and maintains hemostatic platelet counts; however, to date, long-term data are lacking on the outcome of children with ITP who are treated with eltrombopag. This prospective, observational, longitudinal cohort study evaluated the efficacy and safety of eltrombopag in pediatric patients with persistent or chronic ITP. For the 116 pediatric patients enrolled, duration of eltrombopag treatment was at least 3 months. Median effective dose was 25 mg/day, 50 mg/day, and 50 mg/day, respectively, for children age 5 years or younger, 6 to 11 years, or 12 years or older. In all, 89 patients (76.7%) achieved overall response, 53 (45.7%) achieved complete response, and 36 (31.0%) achieved response. Median platelet counts increased by week 1 and were sustained throughout the treatment period. During treatment with eltrombopag, the proportion of patients with grade 1 to 4 bleeding symptoms decreased from 83.61% at baseline to 9.88% at 6 months when only grade 1 was reported. Forty-three patients (37.1%) reported using concomitant medications at study entry, which was reduced to 1 patient (2.5%) who needed concomitant medications at 12 months. All adverse events were grade 1 or 2 according to Common Terminology Criteria for Adverse Events. No serious adverse events, cataracts, malignancies, or thromboses were reported during the study. Long-term treatment with eltrombopag was generally safe, well tolerated, and effective in maintaining platelet counts and reducing bleeding in most pediatric patients with persistent or chronic ITP. Combined with future studies, these findings will help establish how eltrombopag should best be used in the management of pediatric patients with East Asian ancestry.
- 15 March 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (6) , e29006
An escalating treatment strategy for children with severe chronic immune thrombocytopenia: Preliminary report from a single center
Objective: To analyze the effects of escalating treatment strategy in children with severe chronic immune thrombocytopenia (SCITP).Methods: This was a single‐center, retrospective cohort study. Data from children with SCITP who received escalating treatment strategy in our center were collected between June 2017 and August 2019. The escalating strategy included three steps: Step I (six courses of high‐dose dexamethasone [HDD]), Step II (HDD combined with low‐dose rituximab), and Step III (eltrombopag).Results: A total of 30 cases (18 males and 12 females) were included, with duration of immune thrombocytopenia (ITP) of 20.5 (12.0–96.0) months. After treatment, the remission rate was 36.7% (11/30) and the sustained response (SR) rate was 68.2% (15/22). The distribution (remission rates) from Step I to III was as follows: nine of 30 (33.3%, 3/9); four of 30 (50%, 2/4); 17/30 (29.4%, 5/17), respectively. In eltrombopag (Step III) cases, 47.5% (8/17) maintained a platelet count of ≥50 × 109/L, 37.5% (3/8) had dose tapering, and 25% (2/8) have successfully discontinued the medication. The number of patients at 12, 24, and 36 months were 30, seven, and two, with a total response and remission rates of 80% (36.7%), 57.1% (28.6%), and 50% (50%), respectively. The total relapse rate was 26.7% (8/30), and three cases from Step II and five cases from Step III.Conclusion: The escalating strategy for children SCITP showed an effective improvement rate with 36.7% remission and 68.2% SR, and 30% could benefit and retain SR from HDD treatment. Combined treatment with eltrombopag can reduce the relapse rate of low‐dose rituximab.
- 15 March 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (6) , e29006
An escalating treatment strategy for children with severe chronic immune thrombocytopenia: Preliminary report from a single center
Objective: To analyze the effects of escalating treatment strategy in children with severe chronic immune thrombocytopenia (SCITP).Methods: This was a single‐center, retrospective cohort study. Data from children with SCITP who received escalating treatment strategy in our center were collected between June 2017 and August 2019. The escalating strategy included three steps: Step I (six courses of high‐dose dexamethasone [HDD]), Step II (HDD combined with low‐dose rituximab), and Step III (eltrombopag).Results: A total of 30 cases (18 males and 12 females) were included, with duration of immune thrombocytopenia (ITP) of 20.5 (12.0–96.0) months. After treatment, the remission rate was 36.7% (11/30) and the sustained response (SR) rate was 68.2% (15/22). The distribution (remission rates) from Step I to III was as follows: nine of 30 (33.3%, 3/9); four of 30 (50%, 2/4); 17/30 (29.4%, 5/17), respectively. In eltrombopag (Step III) cases, 47.5% (8/17) maintained a platelet count of ≥50 × 109/L, 37.5% (3/8) had dose tapering, and 25% (2/8) have successfully discontinued the medication. The number of patients at 12, 24, and 36 months were 30, seven, and two, with a total response and remission rates of 80% (36.7%), 57.1% (28.6%), and 50% (50%), respectively. The total relapse rate was 26.7% (8/30), and three cases from Step II and five cases from Step III.Conclusion: The escalating strategy for children SCITP showed an effective improvement rate with 36.7% remission and 68.2% SR, and 30% could benefit and retain SR from HDD treatment. Combined treatment with eltrombopag can reduce the relapse rate of low‐dose rituximab.
- Open Access
- 30 November 2020
- Published by Wiley
A second-line escalating treatment strategy for children with severe chronic immune thrombocytopenia: A retrospective data from a single-center
Objective: To analyze the effect of a novel second-line escalating treatment strategy (high-dose dexamethasone (HDD), low-dose rituximab to eltrombopag) for children with severe chronic immune thrombocytopenia (SCITP). Materials and Methods: This study was a single-center, retrospective cohort study. The second-line escalating strategy included 3 steps: Step I (6 courses high-dose dexamethasone: HDD), Step II (HDD combined with low-dose rituximab), and Step III (eltrombopag). Results: A total of 30 cases (18 males and 12 females) were included; the median age was 8.83 (1.42-13.9) year-old, the duration time of ITP was 20.5 (12.0-96.0) months, and the platelet counts were 15 (3-29) ×109/L. After the median 14 (12-37) months’ treatment, the remission rate was 36.7% (11/30), and the sustained response (SR) rate was 68.2% (15/22). In eltrombopag (step III) cases, 47.5% (8/17) maintained platelet ≥50×109/L, 37.5% (3/8) dose tapering, and 25% (2/8) were successfully discontinued from medication. The number of patients at 12th, 24th, and 36th months was 30, 7, and 2, with the total response (TR) and remission rates of 80% (36.7%), 57.1% (28.6%), and 50% (50%), respectively. The total relapse rate was 26.7% (8/30),three cases(75%, 3/4)from Step II and 5 cases (41.7% ,5/12)from Step III, none in Step I. Conclusion: The new second-line escalating strategy for children SCITP has an effective improving rate with 36.7% remission and 68.2% SR; 30% could benefit and retain stable response from HDD treatment. Combined treatment with eltrombopag can reduce the relapse rate of low-dose rituximab.
- 30 November 2020
- Published by Wiley
Open AccessA second-line escalating treatment strategy for children with severe chronic immune thrombocytopenia: A retrospective data from a single-center
Objective: To analyze the effect of a novel second-line escalating treatment strategy (high-dose dexamethasone (HDD), low-dose rituximab to eltrombopag) for children with severe chronic immune thrombocytopenia (SCITP). Materials and Methods: This study was a single-center, retrospective cohort study. The second-line escalating strategy included 3 steps: Step I (6 courses high-dose dexamethasone: HDD), Step II (HDD combined with low-dose rituximab), and Step III (eltrombopag). Results: A total of 30 cases (18 males and 12 females) were included; the median age was 8.83 (1.42-13.9) year-old, the duration time of ITP was 20.5 (12.0-96.0) months, and the platelet counts were 15 (3-29) ×109/L. After the median 14 (12-37) months’ treatment, the remission rate was 36.7% (11/30), and the sustained response (SR) rate was 68.2% (15/22). In eltrombopag (step III) cases, 47.5% (8/17) maintained platelet ≥50×109/L, 37.5% (3/8) dose tapering, and 25% (2/8) were successfully discontinued from medication. The number of patients at 12th, 24th, and 36th months was 30, 7, and 2, with the total response (TR) and remission rates of 80% (36.7%), 57.1% (28.6%), and 50% (50%), respectively. The total relapse rate was 26.7% (8/30),three cases(75%, 3/4)from Step II and 5 cases (41.7% ,5/12)from Step III, none in Step I. Conclusion: The new second-line escalating strategy for children SCITP has an effective improving rate with 36.7% remission and 68.2% SR; 30% could benefit and retain stable response from HDD treatment. Combined treatment with eltrombopag can reduce the relapse rate of low-dose rituximab.
- 1 October 2016
- Vol. 24 (5) , 1598-1602
[Pulsed High-dose Dexamethasone Therapy and Its Application in Children with Immune Thrombocytopenia-Review].
Immune thrombocytopenia (ITP) is the most common immune-mediated acquired bleeding disorders in children. The prognosis of majority of these patient are well, with recent complete remission. However, a few patients are facing the risk of bleeding since they do not respond to the first-line therapy, and need second-line therapy. The present second-line treatments are difficult to be popularized due to their efficacy, side-effects, costs and some other factors. The pulsed high-dose dexamethasone (HDD) therapy with its good effect, small adverse effects and low cost in adults has been used as the first-line therapy in newly diagnosed ITP, which now has attracted the attention of pediatricians. In this review, we briefly summarized the latest progress of pulsed HDD therapy for ITP in children.
- 1 October 2016
- Vol. 24 (5) , 1598-1602
[Pulsed High-dose Dexamethasone Therapy and Its Application in Children with Immune Thrombocytopenia-Review].
Immune thrombocytopenia (ITP) is the most common immune-mediated acquired bleeding disorders in children. The prognosis of majority of these patient are well, with recent complete remission. However, a few patients are facing the risk of bleeding since they do not respond to the first-line therapy, and need second-line therapy. The present second-line treatments are difficult to be popularized due to their efficacy, side-effects, costs and some other factors. The pulsed high-dose dexamethasone (HDD) therapy with its good effect, small adverse effects and low cost in adults has been used as the first-line therapy in newly diagnosed ITP, which now has attracted the attention of pediatricians. In this review, we briefly summarized the latest progress of pulsed HDD therapy for ITP in children.